L-165041 (L165041) is a selective PPARδ agonist with Ki of 6 nM, >120 fold selectivity over PPARγ.
L-165041 inhibits cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.
L-165041 inhibits rat VSMC proliferation in a dose dependent manner by blocking G(1) to S phase progression and repressing the phosphorylation of Rb, also inhibits PDGF-induced expression of cyclin D1 and CDK4.
L-165041 significantly lowers plasma cholesterol without major changes in very low or low density lipoproteins in db/db mice.
